VAXIMM AG
VAXIMM to Participate at Upcoming Industry Events
DGAP-News: VAXIMM AG
/ Key word(s): Conference
VAXIMM to Participate at Upcoming Industry Events Basel (Switzerland) and Mannheim (Germany), January 30, 2020 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced today that the Company will participate in several industry events in the coming months. Company representatives will be available for networking and one-on-one meetings at the following conferences: BIO CEO & Investor Conference VAXIMM representatives will be available for one-on-one meetings during the conference. To schedule a meeting, please use the event partnering system or contact info@vaximm.com. 13th SACHS Annual European Life Science CEO Forum Dr. Heinz Lubenau, CEO, will give a corporate presentation on February 19th at 2:15 pm CET and participate in the panel, “Oncology Advanced Therapies & Diagnostics,” taking place on the same day at 4:30 pm. The Company will also host one-on-one meetings at this event. To request a meeting with VAXIMM, please sign up through the event’s meeting system. 14th Annual International Partnering Conference BIO-Europe Spring(R) VAXIMM plans to give a corporate presentation and host one-on-one meetings at this event. To request a meeting, please sign up through the event’s partneringONE meeting system. 30th MedTech Investing Europe Conference VAXIMM representatives will be available for one-on-one meetings during the conference. Dr. Heinz Lubenau also plans to give a corporate presentation. To schedule a meeting, please contact info@vaximm.com. About VAXIMM VAXIMM also has a neoantigen program currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a strategic clinical trial collaboration with NEC Corporation for the development of personalized neoantigen cancer vaccines. VAXIMM also has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. VAXIMM’s investors include: BB Biotech Ventures, BioMed Partners, CMS, M Ventures, NEC and Sunstone Capital. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. For more information, please see www.vaximm.com. Contact:
30.01.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |